AKT1 and cancer: As robust cell death induction in transformed cells is crucial for effective TRAIL-based anti-cancer therapy, we concluded that interfering with the PI3K/Akt signaling axis or CDKs is most probably insufficient to fully exploit the therapeutic potential of TRAIL in PIK3CA-mutant CRC cells.